Association between copper transporter receptor 1(CTR1) expression and pathologic outcomes in cisplatin (Pt)-treated bladder cancer (BC) patients.
Deepak Kilari(Medical College of Wisconsin), Eric S. Kim(University of Rochester Medicine), Peter Langenstroer(Medical College of Wisconsin), Edward M. Messing(University of Rochester Medical Center), Elizabeth A. Guancial(Harvard University), Chintan Pandya(University of Rochester), Adam James Robin(Medical College of Wisconsin), Kathryn Bylow(Medical College of Wisconsin), Kenneth A. Iczkowski(University of California, Davis)
Cited by 4
Related Papers
Classification of renal cell carcinoma
|Cancer|1997|878
The “Gender Gap” in Authorship of Academic Medical Literature — A 35-Year Perspective
|New England Journal of Medicine|2006|873
The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma
|The American Journal of Surgical Pathology|2020|705
Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study
|The Lancet Oncology|2020|631
Diagnosis, Evaluation and Follow-Up of Asymptomatic Microhematuria (AMH) in Adults: AUA Guideline
|The Journal of Urology|2012|487